Literature DB >> 22008552

Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation.

C T Barry1, M D'Souza, M McCall, S Safadjou, C Ryan, R Kashyap, C Marroquin, M Orloff, A Almudevar, T E Godfrey.   

Abstract

Donor livers are precious resources and it is, therefore, ethically imperative that we employ optimally sensitive and specific transplant selection criteria. Current selection criteria, the Milan criteria, for liver transplant candidates with hepatocellular carcinoma (HCC) are primarily based on radiographic characteristics of the tumor. Although the Milan criteria result in reasonably high survival and low-recurrence rates, they do not assess an individual patient's tumor biology and recurrence risk. Consequently, it is difficult to predict on an individual basis the risk for recurrent disease. To address this, we employed microarray profiling of microRNA (miRNA) expression from formalin fixed paraffin embedded tissues to define a biomarker that distinguishes between patients with and without HCC recurrence after liver transplant. In our cohort of 64 patients, this biomarker outperforms the Milan criteria in that it identifies patients outside of Milan who did not have recurrent disease and patients within Milan who had recurrence. We also describe a method to account for multifocal tumors in biomarker signature discovery.
© 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008552     DOI: 10.1111/j.1600-6143.2011.03788.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  23 in total

Review 1.  Liver transplantation in 2012: Transplantation for liver cancer--more with better results.

Authors:  Chung-Mau Lo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

Review 2.  Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice.

Authors:  Kornelius Schulze; Jessica Zucman-Rossi
Journal:  Hepat Oncol       Date:  2015-07-27

3.  Integrated genomic analysis for prediction of survival for patients with liver cancer using The Cancer Genome Atlas.

Authors:  Yan-Zhou Song; Xu Li; Wei Li; Zhong Wang; Kai Li; Fang-Liang Xie; Feng Zhang
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

4.  Hepatocellular carcinoma beyond Milan criteria: Management and transplant selection criteria.

Authors:  Mohammed Elshamy; Federico Aucejo; K V Narayanan Menon; Bijan Eghtesad
Journal:  World J Hepatol       Date:  2016-07-28

Review 5.  Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus.

Authors:  Tianfu Wen; Chen Jin; Antonio Facciorusso; Matteo Donadon; Ho-Seong Han; Yilei Mao; Chaoliu Dai; Shuqun Cheng; Bixiang Zhang; Baogang Peng; Shunda Du; Changjun Jia; Feng Xu; Jie Shi; Juxian Sun; Peng Zhu; Satoshi Nara; J Michael Millis
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

Review 6.  Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.

Authors:  Matthew M Yeh; Raymond S Yeung; Smith Apisarnthanarax; Renuka Bhattacharya; Carlos Cuevas; William P Harris; Tony Lim Kiat Hon; Siddharth A Padia; James O Park; Kevin M Riggle; Sayed S Daoud
Journal:  World J Hepatol       Date:  2015-06-18

Review 7.  Modulation of immune responses following solid organ transplantation by microRNA.

Authors:  Nayan J Sarma; Venkataswarup Tiriveedhi; Sabarinathan Ramachandran; Jeffrey Crippin; William Chapman; T Mohanakumar
Journal:  Exp Mol Pathol       Date:  2012-10-01       Impact factor: 3.362

8.  Living Donor Liver Transplantation: The Optimal Curative Treatment for Hepatocellular Carcinoma Even Beyond Milan Criteria.

Authors:  Altan Alim; Yalcin Erdogan; Murat Dayangac; Yildiray Yuzer; Yaman Tokat; Arzu Oezcelik
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

9.  A Seven-microRNA Expression Signature Predicts Survival in Hepatocellular Carcinoma.

Authors:  Jian Zhang; Charing C N Chong; George G Chen; Paul B S Lai
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

10.  Risk Score Based on Two microRNAs as a Prognostic Marker of Hepatocellular Carcinoma and the Corresponding Competitive Endogenous RNA Network.

Authors:  Xiao-Chun Huang; Fei-Xiong Pang; Sheng-Song Ou; Xiao-Jiao Wei; Yu-Ju Xu; Yan-Hua Lai
Journal:  Int J Gen Med       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.